Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7421261 | 0.72 | MAP4K4 (0.32) | — | |
| SCHEMBL9260414 | 0.68 | CDK4 (0.42) | CYP3A4LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL6321425 | 0.68 | MAPT (0.54) | CYP3A4LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL22282703 | 0.67 | MAPT (0.41) | CYP3A4LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL28612750 | 0.63 | CYP1A2 (0.36) | CYP3A4LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL27215795 | 0.63 | CYP3A4 (0.47) | CYP3A4LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL29352420 | 0.62 | CYP3A4 (0.39) | CYP3A4LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL56484 | 0.62 | CYP3A4 (0.39) | CYP3A4LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL28969118 | 0.62 | CYP3A4 (0.39) | CYP3A4LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL57173 | 0.62 | CYP3A4 (0.39) | CYP3A4LMNAKDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1066656-A | The Pyridione derivatives that amino acid azelidinyl replaces, its preparation method and as the application of medicine | ESTEVE LABOR DR (ES) | 1992-12-02 | — | — | CN | claimed |
| WO-2023172701-A2 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-108912142-A | Pyrrolo- benzoxazin ketone compound and its injection and the purposes in antithrombotic | 吕烨 | 2018-11-30 | — | — | CN | disclosed |
| US-7550500-B2 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7126010-B2 | Benzylcycloalkyl amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20060069128-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | DUNCIA JOHN V | 2006-03-30 | — | — | US | disclosed |
| US-6992091-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20060014964-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V | 2006-01-19 | — | — | US | disclosed |
| US-6984651-B2 | Piperidine amides as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA, COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| WO-1997036907-A9 | BENZOXAZINES FOR ENHANCING SYNAPTIC RESPONSE | — | 1997-12-04 | — | — | WO | disclosed |
| WO-1997036907-A1 | BENZOXAZINES FOR ENHANCING SYNAPTIC RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0739344-A1 | ANTIPARASITIC PYRROLOBENZOXAZINE COMPOUNDS | PFIZER INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| EP-0739344-A1 | ANTIPARASITIC PYRROLOBENZOXAZINE COMPOUNDS | PFIZER INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995019363-A1 | ANTIPARASITIC PYRROLOBENZOXAZINE COMPOUNDS | PFIZER INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1995019363-A1 | ANTIPARASITIC PYRROLOBENZOXAZINE COMPOUNDS | PFIZER INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1993006108-A1 | PYRROLOBENZOXAZINE DERIVATIVES AS 5-HT AGONISTS AND ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-01 | — | — | WO | disclosed |
| WO-1993006108-A1 | PYRROLOBENZOXAZINE DERIVATIVES AS 5-HT AGONISTS AND ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-01 | — | — | WO | disclosed |
| US-4035495-A | HYPERTENSIVE AGENTS, CNS DEPRESSANT | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-07-12 | — | — | US | disclosed |
| US-4035495-A | HYPERTENSIVE AGENTS, CNS DEPRESSANT | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069128-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | ACKR3, CCL11, CCR2 | CYP3A4 4341/4885LMNA 4339/4885KDM4E 4285/4885 |
| US-20060014964-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR3, CCR1, NR1I3 | CYP3A4 1062/4885LMNA 3395/4885KDM4E 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.